Insulet Corp SEC Filings

Insulet Corporation disclosed the terms of an offer letter for Flavia H. Pease in an Item 5.02 filing. Ms. Pease will receive a Prorated Annual Award split into 75% restricted stock units vesting ratably over three years and 25% stock options vesting ratably over four years. An Equity Sign-On Award will be granted as restricted stock units vesting ratably over three years. She will receive a $1,325,000 cash sign-on award. Her annual base salary will be $715,000 with a 70% target annual bonus and eligibility for severance and change-in-control benefits under the company plan. The Offer Letter is filed as Exhibit 10.1 and a related press release is dated September 16, 2025.

Insulet Corporation (PODD) Form 4 filing: The reporting person, Prem Singh (SVP, Global Operations), sold 687 shares of Insulet common stock on 09/08/2025 at a weighted average sale price of $347.49 per share (sales ranged from $347.35 to $347.51). After the reported sale, Mr. Singh beneficially owned 3,456 shares, held directly. The sale was reported by an attorney-in-fact on behalf of the reporting person and the filer offers to provide breakouts of shares sold at each price upon request.

Insulet Corporation (PODD) Form 4 shows insider transactions by Laetitia Cousin, SVP, Regulatory, Quality & Compliance, dated 09/08/2025. The filing reports the acquisition of 541 shares via an employee stock option exercisable at $276.36 and 256 shares via a separate option exercisable at $166.62, both effective 09/08/2025. The reporting person also acquired 541 and 256 shares (reported as non-derivative acquisitions) at those prices and sold 797 shares on the same date at a weighted average price of $348.81. The filing discloses that 93 of the acquired shares were purchased under the company stock purchase plan since the last Section 16 filing. Following the reported transactions, beneficial ownership figures are shown as 4,431; 4,687; and 3,890 shares on the respective lines. The transactions include annual non-qualified option awards that vest in four substantially equal annual installments.

Insulet Corporation (PODD) filed a Form 144 reporting a proposed sale of 797 common shares through Fidelity Brokerage Services LLC on the NASDAQ with an aggregate market value of $278,000.26. The filing shows the shares were acquired via options granted by the issuer on 02/28/2023 (541 shares) and 02/27/2024 (256 shares) and that payment is noted as cash with an approximate sale date of 09/08/2025. No securities were reported sold by the filer in the past three months. The filer attests they are unaware of any undisclosed material adverse information about the issuer.

Insulet Corporation (PODD) Form 144 notifies of a proposed sale of 687 common shares through Fidelity Brokerage Services with an aggregate market value of $238,718.01, planned for 09/08/2025 on NASDAQ. The shares were acquired by the filer via restricted stock vesting as compensation on 01/10/2025 (308 shares) and 02/27/2025 (379 shares).

The filing also discloses prior sales by the same person, Prem Singh: 2,327 shares sold on 06/13/2025 for $698,216.35 and 1,343 shares sold on 08/07/2025 for $429,760.00. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.

Benjamin Eric, Executive Vice President and Chief Product Experience Officer at Insulet Corporation (PODD), reported the sale of 4,263 shares of Insulet common stock on 08/21/2025 at a price of $332.23 per share. Following the transaction, he beneficially owns 16,736 shares. The Form 4 indicates the sale was made pursuant to an existing Rule 10b5-1 trading plan. The filing also notes that 93 shares were acquired through the company Employee Stock Purchase Plan since his last Form 4. The document is a routine Section 16 disclosure of an insider sale under a pre-established plan and does not disclose additional transactions, derivatives, or other compensatory details.

Michael R. Minogue, a director of Insulet Corporation (PODD), reported multiple transfers of common stock on 08/19/2025 and 08/21/2025. The Form 4 shows transfers described as coming from a GRAT and as bona fide gifts to a trust for the reporting person’s spouse, who is trustee. The filing lists several paired dispositions and acquisitions of 9,459 and 1,380 shares (transaction code G, gift/transfer). The report discloses post-transaction beneficial ownership amounts including 778 shares held directly and 15,453 shares held indirectly by trust, along with intermediate reported balances (e.g., 11,617, 14,073). The signature is by attorney-in-fact John W. Kapples dated 08/21/2025.

Insulet Corporation (PODD) Form 144 reports a proposed sale of 4,263 shares of common stock through Fidelity Brokerage Services on NASDAQ with an aggregate market value of $1,416,296.49 and an approximate sale date of 08/21/2025. The filing shows the shares to be sold were recently acquired by the seller through restricted stock vesting on 02/14/2025 (2,842 shares), 02/27/2025 (806 shares), and 02/28/2025 (615 shares), with consideration recorded as compensation. No securities were reported sold by the same person in the prior three months. The filer attests they are not aware of any undisclosed material adverse information about the issuer.

Capital Research Global Investors reports beneficial ownership of 4,736,127 shares of Insulet Corporation, equal to 6.7% of the company's outstanding common stock. The filing shows sole voting power for 4,730,490 shares and sole dispositive power for 4,736,127 shares, with no shared voting or dispositive authority reported.

The statement classifies the filer as an investment adviser and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. This is a routine institutional ownership disclosure reflecting a material passive stake above the 5% threshold.